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ABSTRACT
Introduction: Our objective was to describe the
contemporary outcomes of orbital atherectomy
(OA) vs. rotational atherectomy (RA) use for
inpatient percutaneous coronary intervention
(PCI) in the United States. Data on the use of
OA vs. RA in contemporary inpatient PCI are
limited.
Methods: We queried the Nationwide Read-
mission Database (NRD) from January to
November for the years 2016–2017 to identify
hospitalizations of patients who underwent PCI
with atherectomy. We conducted a multivariate
regression analysis to identify variables associ-
ated with in-hospital mortality.
Results: We included 77,040 records of patients
who underwent inpatient PCI with atherec-
tomy. Of those, 71,610 (93%) had RA, and 5430
(7%) had OA. There was no significant change
in the trend of using OA or RA over 2016 and
2017. OA was less utilized in patients presenting
with ST-segment elevation myocardial infarc-
tion (STEMI) (4.3% vs. 46.8%, p\0.001). In our
cohort, OA was associated with lower in-hospi-
tal mortality (3.1% vs. 5%, p\0.001) and
30-day urgent readmission (\ 0.01% vs. 0.2%,
p = 0.009), but a higher risk of coronary
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perforation (1.7% vs. 0.6%, p\0.001) and car-
diac tamponade (1% vs. 0.3%, p\0.001) and a
higher cost of index hospitalization ($28,199 vs.
$23,188, p\0.001) compared with RA.
Conclusion: RA remains the predominant
atherectomy modality for inpatient PCI in the
United States (93%). There was no change in the
trend of use for either modality over the years
2016 and 2017. OA was noted to have a lower
incidence of in-hospital death, but a higher risk
of coronary perforation and a higher cost of
index hospitalization for the overall unmatched
cohorts.
Keywords: Atherectomy; Orbital atherectomy;
Rotational atherectomy
Key Summary Points
RA was the predominant atherectomy tool
used for inpatient PCI in 2016 and 2017 in
the United States (93%).
There was no significant change in the
trends of using OA or RA for inpatient PCI
for 2016 and 2017.
OA was most likely to be used in large and
teaching hospitals and not in the STEMI
setting. In unmatched cohorts, despite a
higher incidence of coronary perforation
and tamponade, OA was associated with a
lower incidence of in-hospital mortality.
OA was associated a lower incidence of
30-day urgent readmission, ischemic
stroke, complete heart block, and
ventricular tachycardia, but with a higher
hospital cost.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13643225
INTRODUCTION
Severe coronary artery calcification is a signifi-
cant risk factor for procedural failure and com-
plications, and long-term adverse events in
contemporary percutaneous coronary interven-
tion (PCI) [1–3]. The prevalence of moderate to
severe calcification in patients undergoing PCI
is around 20% angiographically [4]. Different
calcium-specific technologies are available to
address coronary calcification, including
atherectomy devices and, more recently,
intravascular lithotripsy, which is yet to be
approved for coronary use in the United States
[5]. The main contemporary indication of
atherectomy devices is the preparation of the
vessel for subsequent balloon angioplasty and
stenting.
Rotational atherectomy (RA) (Boston Scien-
tific, Natick, MA, USA) has been the traditional
modality for treating calcified coronary lesions
in the United States for the past three decades.
RA uses a rotating abrasive burr at high speeds
to ablate and crack superficial calcium [6].
Orbital atherectomy (OA) (Cardiovascular Sys-
tems, Inc., St. Paul, MN, USA) was approved in
2013 as an adjunctive tool for PCI in heavily
calcified vessels [7]. It uses a drive shaft with an
eccentrically mounted crown to perform proxi-
mal and distal sanding that is abrasive only to
fibrotic and calcified vessels, minimizing dam-
age to the medial layer of the vessel [8]. Both
modalities help enlarge the lumen and enhance
equipment delivery. We performed a compre-
hensive analysis of the Nationwide Readmis-
sions Database (NRD) to describe the outcomes
of RA and OA.
METHODS
Data Source
We used the Nationwide Readmissions Database
(NRD) of the Healthcare Cost and Utilization
Project (HCUP), Agency for Healthcare Research
and Quality, to obtain our cohort [9]. The NRD
contains discharge data from 28 geographically
dispersed states, accounting for 60.0% of the
total US resident population and 58.2% of all US
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hospitalizations. We identified our cohort,
procedures, and outcomes using the Interna-
tional Classification of Diseases, Tenth Revision,
Clinical Modification (ICD-10-CM) and Proce-
dure Coding System (ICD-10-PCS) codes along
with ICD-10 Clinical Classifications Software
(CCS). The codes used are summarized in
Table S1.
Study Population
We identified our cohort using the ICD-10
codes for OA and RA used for inpatient PCI for
the years 2016 and 2017 (Table S1). Patient and
hospital-level variables provided by HCUP NRD
were used to identify demographics and base-
line characteristics. The Elixhauser method was
used to assess comorbidities [10]. Additional
comorbidities were identified using appropriate
ICD-10-CM codes (Table S1). We excluded
patients with missing data on in-hospital mor-
tality, who had combined RA and OA, and
whose admission month was December to be
able to assess the 30-day readmission rate. The
NRD is a publicly available database with de-
identified hospitalization records; therefore, the
study was exempt from institutional review
board evaluation at Banner University Medical
Center.
Outcomes
The primary outcome of our study was in-hos-
pital mortality. Secondary outcomes included
in-hospital coronary artery bypass graft surgery
(CABG), coronary perforation, ischemic or
hemorrhagic stroke, vascular complications,
renal complications, discharge to a nursing
facility, length of hospital stay, the cost of index
hospitalization, and non-elective 30-day
readmission.
Statistical Analysis
All analyses were conducted using the appro-
priate weighting, stratifying, and clustering
samples following HCUP regulations [11, 12].
Given the extreme heterogeneity between the
two groups, we did not perform propensity-
score matching and aimed to report outcomes
in a descriptive fashion. Continuous variables
are summarized as medians and interquartile
range (IQR) (25th and 75th percentiles) and
compared with the Mann–Whitney U test. Cat-
egorical variables are displayed as numbers and
percentages and compared with Pearson’s chi-
square or Fisher’s exact tests. Outcomes in the
matched groups were reported as odds ratios
(OR) with a 95% confidence interval (CI). All
p values are two-sided, with a significance
threshold\0.05.
We performed a multivariable regression
analysis to identify variables associated with in-
hospital mortality. We included all variables
considered significant based on background
knowledge using the Enter method. The list of
the variables used is shown in Table S2. Analysis
of readmissions was performed for patients
without in-hospital death at the index admis-
sion. Statistical analysis was performed using
IBM SPSS Statistics for Windows (version 25.0;
IBM Corp, Armonk, NY). The data sets gener-
ated and/or analyzed during the current study




We identified 84,401 total weighted hospital-
izations for patients who underwent PCI with
atherectomy during the study period. After the
exclusion of patients who were admitted in
December and those with missing in-hospital
mortality data, our final cohort included 77,040
hospitalizations (Fig. S1). RA was the predomi-
nant modality of atherectomy in 71,610 records
(93%), while OA was used in 5430 (7%) of the
cases. Differences in demographics, comorbidi-
ties, and hospital characteristics between the
OA and RA groups are shown in Table 1. Over
2016 and 2017, there was no significant change
in the trends of using OA (p trend = 0.35) or RA
(p trend = 0.24) (Fig. 1).
Median patient age was 65 (IQR 56–74) years,
and 29.2% were women. Of these patients,
about 43.8% presented with ST-elevation
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Age, median (IQR) 65 (56–74) 73 (66–80) 64 (55–74) \ 0.001
Gender (female) [n (%)] 22,460 (29.2%) 2,000 (36.8%) 20,460 (28.6%) \ 0.001
Elective admission [n (%)] 8,355 (10.8%) 1244 (23.2%) 7111 (10%) \ 0.001
STEMI [n (%)] 33,731 (43.8%) 233 (4.3%) 33,498 (46.8%) \ 0.001
NSTEMI [n (%)] 18,804 (24.4%) 1578 (29.1%) 17,226 (24.1%) \ 0.001
Morbid obesity [n (%)] 4328 (5.6%) 327 (6%) 4000 (5.6%) 0.178
Hypertension [n (%)] 47,468 (61.6%) 3664 (67.5%) 43,803 (61.2%) \ 0.001
Atrial fibrillation/flutter
[n (%)]
11,915 (15.5) 1119 (20.6%) 10,796 (15.1%) \ 0.001
Renal failure, n (%) 13,436 (17.4%) 1620 (29.8%) 11,816 (16.5%) \ 0.001
End-stage renal disease, n (%) 2801 (3.6%) 415 (7.6%) 2386 (3.3%) \ 0.001
Chronic liver disease [n (%)] 1477 (1.9%) 150 (2.8%) 1326 (1.9%) \ 0.001
Chronic lung disease [n (%)] 14,064 (18.3%) 1410 (26%) 12,654 (17.7%) \ 0.001
Diabetes mellitus (%) 28,501 (37%) 2671 (49.2%) 25,830 (36.1%) \ 0.001
Anemia [n (%)] 11,057 (14.4%) 1290 (23.8%) 9768 (13.6%) \ 0.001
History of ICD [n (%)] 1464 (1.9%) 148 (2.7%) 1315 (1.8%) \ 0.001
History of cardiac pacemaker
[n (%)]
1792 (2.3%) 225 (4.1%) 1567 (2.2%) \ 0.001
Prior PCI [n (%)] 1441 (1.9%) 130 (2.4%) 1,311 (1.8%) 0.004
Prior CABG [n (%)] 7005 (9.1%) 652 (12%) 6353 (8.9%) \ 0.001
Bifurcation [n (%)] 2966 (3.8%) 294 (5.4%) 2672 (3.7%) \ 0.001
Prior stroke [n (%)] 5020 (6.5%) 509 (9.4%) 4510 (6.3%) \ 0.001
Carotid artery disease [n (%)] 52 (0.1%) 3 (0.1%) 48 (0.1%) 1
Congestive heart failure
[n (%)]
1479 (1.9%) 169 (3.1%) 1310 (1.8%) \ 0.001
Peripheral artery disease
[n (%)]
9129 (11.8%) 1105 (20.3%) 8023 (11.2%) \ 0.001
Prior MI [n (%)] 13,225 (17.2%) 976 (18%) 12,249 (17.1%) 0.104
Impella use [n (%)] 3100 (4%) 406 (7.5%) 2694 (3.8%) \ 0.001
Intra-aortic balloon pump
[n (%)]
5491 (7.1%) 239 (4.4%) 5252 (7.3%) \ 0.001
Intravascular imaging [n (%)] 838 (15.4%) 7115 (9.9%) \ 0.001
Use of vasopressors [n (%)] 900 (1.2%) 44 (0.8%) 856 (1.2%) 0.012
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myocardial infarction (STEMI). PCI of bifurca-
tion lesions occurred in 3.8%. Impella was used
in 4% of records, while intra-aortic balloon
pump was used in 7.1%. Intravascular imaging
was used in 9.8% of cases (intravascular ultra-
sound [IVUS] in 9.2% and optical coherence
tomography [OCT] in 0.6%).
Patients who had OA were older (73 vs.
64 years, p\0.001) and were more likely to be
women (36.8% vs. 28.6%, p\ 0.01). OA was
significantly less utilized in patients presenting
with STEMI (4.3% vs. 46.8%, p\0.01), and
more utilized in patients with prior CABG (12%
vs. 8.9%, p\ 0.01), bifurcation lesions (5.4% vs.
3.7%, p\0.01). Both Impella (7.5% vs. 3.8%,
p\0.01) and intravascular imaging including
IVUS (13.5% vs. 9.5%, p\0.01) and OCT (2.3%
vs. 0.5%, p\ 0.01) were more likely to be used
with OA. OA was more used in large (68.2% vs.
63%, p\0.01) and teaching hospitals (79.7%
vs. 70.1%, p\ 0.01).
Outcomes
Study outcomes are summarized in Table 2. The
incidence of in-hospital mortality and cardio-
genic shock was 4.9% and 10.8%, respectively.
The incidence of ischemic and hemorrhagic
strokes was 0.9% and 0.3%, respectively.
Coronary perforation occurred in 0.7%. The
incidence of 30-day urgent readmission was
0.2%.
OA was associated with a lower incidence of
in-hospital mortality (3.1% vs. 5%, p\0.01),
in-hospital CABG (1.4% vs. 1.9%, p = 0.029),
discharge to a facility (7.1% vs. 11.5%,
p\0.01), and 30-day urgent readmissions (0%
vs. 0.2%, p = 0.01). However, it was associated
with a higher incidence of coronary perforation
(1.7% vs. 0.6%, p\ 0.01) and cardiac tampon-
ade (1% vs. 0.3%, p\0.01). OA was also asso-
ciated with a slightly longer LOS (4 vs. 3 days,
p\0.01) and higher cost of index hospitaliza-
tion ($28,199 vs. $23,188, p\ 0.01) compared
with RA. On multivariable regression analysis,
OA was associated with a lower incidence of in-
hospital mortality (OR 0.651, 95% CI
[0.540–0.784], p\ 0.01). Variables associated
with in-hospital mortality are shown in
Table S3.
DISCUSSION
The main findings of the study can be summa-
rized as follows: (1) RA was the predominant
atherectomy tool used for inpatient PCI in 2016
and 2017 in the United States (93%). (2) There









Cardiac arrest [n (%)] 6647 (8.6%) 259 (4.8%) 6388 (8.9%) \ 0.001
Cardiogenic shock [n (%)] 8287 (10.8%) 283 (5.2%) 8004 (11.2%) \ 0.001
Drug-eluting stents [n (%)] 60,948 (79.1%) 4923 (90.7%) 56,025 (78.2%) \ 0.001
Large hospital [n (%)] 48,807 (63.4%) 3702 (68.2%) 45,105 (63%) \ 0.001
Teaching hospital [n (%)] 54,500 (70.7%) 4329 (79.7%) 50,171 (70.1%) \ 0.001
Medicare [n (%)] 40,792 (52.9%) 4173 (76.9%) 36,619 (51.1%) \ 0.001
IQR interquartile range, ICD implantable cardioverter-defibrillator, PCI percutaneous coronary intervention, CABG
coronary artery bypass surgery, MI myocardial infarction, STEMI ST-segment elevation myocardial infarction, NSTEMI
non-ST-segment elevation myocardial infarction
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OA or RA for inpatient PCI for 2016 and 2017.
(3) OA was most likely to be used in large and
teaching hospitals and not in the STEMI setting.
(4) In unmatched cohorts, despite a higher
incidence of coronary perforation and tam-
ponade, OA was associated with a lower inci-
dence of in-hospital mortality, 30-day urgent
readmission, ischemic stroke, complete heart
block, and ventricular tachycardia, but with a
longer LOS and a higher cost of index hospi-
talization, compared with RA.
Coronary artery calcification is associated
with a higher risk of target lesion revascular-
ization (TLR) and major adverse cardiovascular
events (MACE) after PCI, even with newer-gen-
eration drug-eluting stents (DES) [13]. RA has
been the primary modality used to deal with
calcified arteries, although improvement of
long-term outcomes with this device has not
been demonstrated [14]. The approval of the
Diamondback 360 OA system in 2013 intro-
duced a new tool in the armamentarium of the
interventional cardiologist against coronary
calcification. In the ORBIT II ‘‘Evaluate the
Safety and Efficacy of OAS in Treating Severely
Calcified Coronary Lesions’’ trial, OA use was
associated with a low incidence of TLR up to
3 years (7.8%), but the study lacked a control
arm [15]. Both devices are currently used in
contemporary practice to treat coronary calcifi-
cation. In our analysis, the predominant
atherectomy modality was RA (93%), which can
be attributed to the comfort level, lower cost,
and experience of operators in using the device
as well as the lack of randomized data for the
OA system.
In our matched cohort and after robust
multivariate regression analysis, the OA system
was associated with reduced risk of in-hospital
mortality, which is similar to the results of the
largest study to date comparing the two
modalities [16]. This finding, however, should
be interpreted with extreme caution given the
retrospective nature and the risk of selection
bias in our study. In our analysis, OA was also
associated with a lower risk of ischemic stroke,
Fig. 1 Trends in use of rotational atherectomy and orbital atherectomy for inpatient percutaneous coronary intervention in
the United States in 2016 and 2017
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Table 2 Outcomes of orbital and rotational atherectomy in patients undergoing inpatient percutaneous coronary inter-
vention in 2016 and 2017











140 (0.2%) 2 (\ 0.01%) 128 (0.2%) 0.01
Discharge to a facility
[n (%)]
5,691 (7.4%) 625 (11.5%) 5066 (7.1%) \ 0.01
Ischemic stroke
[n (%)]
672 (0.9%) 36 (0.7%) 637 (0.9%) 0.10
Hemorrhagic stroke,
n (%)
212 (0.3%) 10 (0.2%) 203 (0.3%) 0.23
Transient ischemic
attack [n (%)]
192 (0.2%) 19 (0.3%) 173 (0.2%) 0.12
In-hospital CABG
[n (%)]
1404 (1.8%) 78 (1.4%) 1325 (1.9%) 0.03
Cardiac tamponade
[n (%)]
289 (0.4%) 54 (1%) 236 (0.3%) \ 0.01
Coronary perforation
[n (%)]
533 (0.7%) 93 (1.7%) 440 (0.6%) \ 0.01
Ventricular
tachycardia [n (%)]




2211 (2.9%) 73 (1.3%) 2138 (3%) \ 0.01
Acute kidney injury
[n (%)]
12,279 (15.9%) 1012 (18.6%) 11,267 (15.7%) \ 0.01




83 (0.1%) 7 (0.1%) 77 (0.7%) 0.67
Retroperitoneal
bleeding [n (%)]
138 (0.2%) 9 (0.2%) 129 (0.2%) 1.00
Post-procedural
bleeding [n (%)]
1307 (1.7%) 137 (2.5%) 1170 (1.6%) \ 0.01
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ventricular tachycardia, and complete heart
block. The lower in-hospital mortality with OA
can be secondary to the lower incidence of
periprocedural myocardial infarction (MI) with
OA compared with RA that was demonstrated
by Meraj et al. [16]. RA uses a burr that is always
in contact with the plaque, not allowing blood
and debris to flow beyond the burr, increasing
the risk of thermal injury, platelet activation,
distal ischemia, no-reflow phenomenon, and
periprocedural MI. On the contrary, OA crown
allows blood and particulates to flow during and
between activations, reducing the risk of ische-
mia, distal embolization, and complete heart
block. The other possible explanation is the
higher risk of burr entrapment of RA, as the RA
only ablates in an antegrade fashion, increasing
the risk of burr entrapment. The bidirectional
ablation ability with the OA, combined with the
small crown size, minimizes the risk of crown
entrapment.
In our analysis, OA was associated with a
higher risk of coronary perforation and peri-
cardial tamponade, which was not previously
detected in studies comparing the two modali-
ties [16, 17]. These studies, however, demon-
strated a strong trend towards a higher risk of
perforation with OA but were not powerful
enough to show statistical significance with
such a rare clinical event [17]. The higher risk of
perforation with OA can have multiple expla-
nations. First, OA results in more modification
of the plaque with longer cuts and deeper dis-
sections compared with RA, as shown by
intravascular imaging [18]. Second, in the
ORBIT II study, vessels smaller than 2.5 mm
were excluded as the 1.25 mm crown might lead
to perforation in such small vessels. It is possible
that in real-life, operators used OA for smaller
vessels leading to more perforations. Finally,
operators might opt to use OA rather than RA in
vessels with eccentric calcific plaques. In
eccentric plaques, the wire bias can be exag-
gerated and using RA in these circumstances
increases the risk of asymmetric ablation, burr
entrapment and vessel perforation. These risks
are reduced with OA as the orbital movement of
the crown may overcome these issues. However,
the preferential use of OA in eccentric plaques
that are already a risk factor of perforation
might lead to increased risk of perforation with
OA in a non-randomized real-world study like
ours.
OA is more efficient to use because it is easier
to set up than RA, and the ViperWire can be
used to deliver equipment, in contrast to the
ROTAWire, which may not provide enough
support. Moreover, the ViperWire is easier to
use for primary lesion crossing than the ROTA-
Wire, which requires crossing the lesion with a
workhorse wire, then exchange through a
microcatheter or over the wire balloon. This was
reflected in reduced fluoroscopy time with OA
compared with RA in prior studies [16, 17]. The
luminal gain with RA is related to the burr size,
and if a larger lumen is needed, more devices are
required, which can be costly and time-con-
suming. Moreover, the larger burrs (1.75 mm)
Table 2 continued






and mean ± SD)
(days)
3 (2–5) 4 (2–7) 3 (2–5) \ 0.01
Cost, median (IQR)
(dollars)
$23,467 ($17,311–$34,876) $28,199 ($19,725–$42,910) $23,188 ($17,184–$34,302) \ 0.01
IQR interquartile range, MI myocardial infarction, CABG coronary artery bypass graft, LOS length of stay, OR odds ratio,
CI confidence interval, SD standard deviation
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require 7F guiding catheters, which can be
challenging to use in certain situations (e.g.,
radial approach in patients with smaller radial
arteries). Conversely, with OA, increasing the
speed of rotation and slowing advancement can
help achieve larger luminal gains without the
need to exchange the device, and it can be done
through a 6F guiding catheter [19]. On the other
hand, OA has certain limitations, including
unclear data regarding use in small (\2.5 mm)
or large ([4.0 mm) vessels, and limitations in
ablation in cases of subtotal occlusion of calci-
fied vessels, as the ablative crown is proximal to
the tip. However, a previous report showed the
feasibility of OA in that situation [20].
The principal advantage that OA has intro-
duced to the field is that the orbital technology
allows the treatment of the entire vessel,
removing calcium more effectively and result-
ing in deeper and longer dissections throughout
the entire artery, compared with RA that ablates
only a fixed diameter of the vessel according to
the burr size [18]. This results in better stent
expansion and apposition compared with RA, as
shown by intravascular imaging [18]. The
anticipated benefit of these findings in terms of
improved long-term outcomes and reduction in
TLR is yet to be shown in a randomized trial.
However, in a study comparing the two
modalities in Japan, OA had a significantly
lower risk of TLR at one year compared with RA
(5.0 vs. 15.7%) [21]. The ECLIPSE
[NCT03108456] trial is currently enrolling
patients and would shed more light on the
long-term outcomes of OA.
A major limitation to the widespread use of
OA is the cost. In our analysis, OA was associ-
ated with a higher cost of index hospitalization
compared with RA ($28,199 vs. $23,188). This
can be attributed to the higher cost of the OA
device compared with the RA device. Although
with OA there is no need to use multiple devices
if a larger luminal gain is needed, unlike RA, this
still did not translate into a lower cost in our
analysis. However, OA was found to be cost-ef-
fective in the Japanese healthcare system, given
better clinical outcomes at 1 year [21]. Another
cost analysis of the ORBIT II trial showed that
OA is cost-effective compared with standard
treatment and can be cost-saving in the
inpatient setting [22]. More studies are needed
to establish the clinical efficacy and cost-effec-
tiveness of OA.
Limitations
Our study has limitations. First, the goal of our
study is to describe rather than compare the two
modalities, given the extreme heterogeneity in
both groups and the lack of necessary patient
and lesion characteristics required to perform
proper propensity-score matching, including
severe calcification, eccentric plaque, and tor-
tuosity. Second, our study is a retrospective
observational study with its inherent limitation
of selection bias. The selection bias may have
affected our results, which should be inter-
preted as descriptive rather than comparative.
Third, given the administrative database struc-
ture of NRD, the study is subject to coding
errors. Fourth, our study describes only inpa-
tient PCIs. Finally, long-term outcomes,
including TLR and long-term mortality, could
not be analyzed.
CONCLUSIONS
RA remains the predominant atherectomy
modality for inpatient PCI in the United States
(93%). There was no change in the trend of use
for either modality over the years 2016 and
2017. Orbital atherectomy was noted to have a
lower incidence of in-hospital death, but a
higher risk of coronary perforation and a higher
cost of index hospitalization for the overall
unmatched cohorts.
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